GYP2D6 phenotype and the metabolism of nicotine and cotinine

Pharmacogenetics

Volumn 6, Issue 3, 1996, Pages 239-242

  Benowitz, Neal L ^a   Jacob III, Peyton ^b   Perez Stable, Eliseo ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Cotinine; CYP2D6; Metabolism; Nicotine

Indexed keywords

COTININE; CYTOCHROME P450 ISOENZYME; DEUTERIUM; DEXTROMETHORPHAN; NICOTINE; STABLE ISOTOPE; CYTOCHROME P450 2D6;

ADULT; AGE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ETHNOLOGY; FEMALE; GENDER; GENETIC POLYMORPHISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; GENETICS; METABOLISM;

ADULT; COTININE; CYTOCHROME P-450 CYP2D6; HUMANS; NICOTINE;

EID: 0029661559     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199606000-00006     Document Type: Article

References (15)

1. Benowitz NL, Jacob P, III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 1994: 56, 483-493.
2. Benowitz NL, Jacob P, III, Fong I, Gupta S. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Ther 1994: 268, 296-303.
3. Benowitz NL, Jacob P, III, Sachs DPL. Deficient C-oxidation of nicotine. Clin Pharmacol Ther 1995: 57, 590-594.
4. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, III, Benowitz NL. Metabolism of nicotine by human liver microsomes: Stereoselective formation of trans-nicotine-N'-oxide. Chem Res Toxicol 1992: 5, 639-646.
5. Cholerton S, Arpanahi A, McCracken N, Boustead C, Taber H, Johnstone K, Leathart J, Daly AK, Idle JR. Poor metabolisers of nicotine and CYT2D6 polymorphism. Lancet 1994: 343, 62-65.
6. Cohen J, ed. Statistical power analysis for the behavioral sciences. Orlando: Academic Press. Inc., 1977: 42-45.
7. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994: 102(Suppl 9), 55-61.
8. Flammang AM, Gelboin HV, Aoyama T, Gonzalez FJ, McCoy GD. Nicotine metabolism by cDNA-expressed human cytochrome P-450s. Biochem Arch 1992: 8, 1-8.
9. Gonzalez FJ. Human cytochromes P450: problems and prospects. TiPS 1992: 13, 346-352.
10. Jacob P, III, Benowitz NL, Shulgin AT. Synthesis of optically pure deuterium-labelled nicotine, nornicotine and cotinine. J Labelled Comp Radiopharm 1988: 25, 1117-1128.
11. 2 in humans. Boil Mass Spectrom 1991: 20, 247-252.
12. McCracken NW, Cholerton S, Idle JR. Cotinine formation by cDNA-expressed human cytochromes P450. Med Sci Res 1992: 20, 877-878.
13. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991: 50, 308-313.
14. Schmid B, Bircher J, Preisig R, Kupfer A. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 1985: 38, 618-624.
15. Turgeon J, Labbe L, Lefez C, LeBel M, Debrisoquine metabolic ratio (DMR) distribution differs among smokers and nonsmokers (Abstr.). Clin Pharmacol Ther 1995: 57, 150.